Veracyte公司首席执行官和首席执行官在收益丰厚和股票表现良好的情况下出售股票。 CEO and CFO of Veracyte sold shares amid strong earnings and positive stock performance.

2025年12月4日, Veracyte CEO Marc Stapley 出售7 668股,每股47.09美元,股份减少2.35%,而CFO Rebecca Chambers则以46.84美元出售13 278股,将她的股份削减10.81%。 On December 4, 2025, Veracyte CEO Marc Stapley sold 7,668 shares at $47.09 each, reducing his stake by 2.35%, while CFO Rebecca Chambers sold 13,278 shares at $46.84, cutting her holding by 10.81%. 这两笔交易都向证交会申报。 Both transactions were filed with the SEC. 据该公司报告,11月4日,第三季度收入强劲,EPS收入51美元,收入1.3187亿美元,比上一年增加13.8%。 The company reported strong third-quarter earnings on November 4, with $0.51 EPS and $131.87 million in revenue, up 13.8% year-over-year. Veracatete的股票于12月4日以47.41美元关闭, 下跌了0.34美元, 市场上限为37.5亿美元, Veracyte’s stock closed at $47.41 on December 4, down $0.34, with a market cap of $3.75 billion and a consensus “Moderate Buy” rating.